# A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

> **NCT07155174** · PHASE2 · RECRUITING · sponsor: **AbbVie** · enrollment: 180 (estimated)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** ABBV-706
- **DRUG:** Atezolizumab
- **DRUG:** Etoposide
- **DRUG:** Carboplatin
- **DRUG:** Carboplatin
- **DRUG:** Lurbinectedin

## Key facts

- **NCT ID:** NCT07155174
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-25
- **Primary completion:** 2029-05
- **Final completion:** 2031-09
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07155174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07155174, "A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07155174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*